Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Current Oncology (Toronto, Ont.)|July 26, 2024
Improving Care for Older Adults with Cancer in Canada: A Call to ActionSarah Cook, Shabbir Alibhai, Rajin Mehta, et al.
International Journal of Cancer|April 12, 2021
Systemic toxicities of trastuzumab-emtansine predict tumor response in HER2+ metastatic breast cancerShou-Ching Tang, Carter L Capra, Germame H Ajebo, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 13, 2018
Feasibility of using a pragmatic trials model to compare two primary febrile neutropenia prophylaxis regimens (ciprofloxacin versus G-CSF) in patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer (REaCT-TC)Mark Clemons, Sasha Mazzarello, John Hilton, et al.
International Journal of Cancer|June 9, 2025
Safety and efficacy of docosahexaenoic acid supplementation during neoadjuvant breast cancer therapy: Findings from the phase II, double-blind, randomized controlled DHA-WIN trialJaqueline Munhoz, Marnie Newell, Gilbert Bigras, et al.
Canadian Family Physician Medecin De Famille Canadien|February 17, 2018
Simplified guideline for prescribing medical cannabinoids in primary careG Michael Allan, Jamil Ramji, Danielle Perry, et al.
BMC Cancer|October 11, 2021
Rationale and design of the Diet Restriction and Exercise-induced Adaptations in Metastatic breast cancer (DREAM) study: a 2-arm, parallel-group, phase II, randomized control trial of a short-term, calorie-restricted, and ketogenic diet plus exercise during intravenous chemotherapy versus usual careAmy A Kirkham, Karen King, Anil A Joy, et al.
Breast (Edinburgh, Scotland)|April 26, 2021
A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropeniaMark Clemons, Dean Fergusson, Anil A Joy, et al.
BMJ Open|September 19, 2019
Comparing docosahexaenoic acid (DHA) concomitant with neoadjuvant chemotherapy versus neoadjuvant chemotherapy alone in the treatment of breast cancer (DHA WIN): protocol of a double-blind, phase II, randomised controlled trialMarnie Newell, John R Mackey, Gilbert Bigras, et al.
Pageof 3